Selected compounds in development targeting cancer metabolism processes. (A) Being acquired by Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA); (B) Cephalon, which obtained GMX1777 in its acquisition of Gemin X Pharmaceuticals Inc., said the program is under evaluation; Source: BCIQ: BioCentury Online Intelligencce